1278results about "Genital tract cells" patented technology

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

The invention provides recombinant human III-type collagen which is of a triple-helix structure and assembled into collagenous fibers and application of the recombinant human III-type collagen, and belongs to the technical field of bioengineering. Collagen fragments capable of forming a triple helix structure are screened out through a bioinformatics algorithm, the fragments are connected in series, a key C-terminal structural domain and a specific amino acid sequence are combined, and formation of a stable triple helix advanced structure and assembly of collagenous fibers are effectively promoted. The recombinant human III type collagen is efficiently expressed through a eukaryotic expression system, and shows excellent stability, low immunogenicity and good biocompatibility. Experimental results show that the prepared recombinant human III-type collagen not only has a natural triple helix structure, but also can be further assembled into macromolecular collagen fibers, is suitable for multiple fields such as medical beauty, bioengineering and tissue repair, and has wide application prospects and market values.

The invention discloses a site for stably expressing protein in a CHO cell gene NW023276806.1 and application of the site, and belongs to the technical field of biological genes. The site belongs to a fixed position in a CHO cell genome, different protein genes are introduced based on a micro-homologous end connection mechanism through a CRISPR / Cas9 tool, and stable expression is carried out. By adopting a site-specific integration method, a target gene is integrated to a stable expression area in a site-specific manner, repeated high-expression monoclonal screening is effectively avoided, and an MMEJ mechanism is introduced to integrate a donor fragment, so that the research and development time for constructing a stable expression cell strain in biological pharmacy can be effectively shortened, and the cost is reduced.

The invention relates to the technical field of recombinant protein expression, in particular to recombinant human-derived III-type collagen as well as a preparation method and application thereof. The invention provides a recombinant human source III type collagen. The amino acid sequence of the recombinant human source III type collagen is shown as SEQ ID NO. 1. The recombinant human-derived III-type collagen prepared by the invention can be better applied to a human body, better exerts biological functions of the collagen, avoids repulsive interaction, is high in safety, can effectively promote cell proliferation and oxidation resistance, and is high in expression yield, stable in batches and good in quality; the recombinant human III type collagen prepared by the invention has the potential of being applied to preparation and production of biological medicines and cosmetics.

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

The invention belongs to the technical field of biological medicine, and particularly relates to a prostate cancer organoid culture medium, a preparation method thereof, a prostate cancer organoid and a culture method thereof. The prostate cancer organ culture medium provided by the invention comprises a basic culture medium and a culture additive, and the culture additive comprises FGF-10 (Fibroblast Growth Factor), Zeaxanthin dipalmitate and Polydatin. In the prostate cancer organoid culture medium provided by the invention, the success rate of organoid culture is greatly improved by utilizing the synergistic effect of the FGF-10, the Zeaxanthin dipalmitate and the Polydatin, the cultured prostate cancer organoid is high in growth speed, the passage frequency is remarkably improved, in-vitro culture can be specifically carried out on prostate cancer tissues of people, and the prostate cancer organoid culture medium has the advantages that the prostate cancer tissue culture efficiency is improved; the survival rate and the formation efficiency of the prostatic cancer organs are further improved.

The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.

Methods, compositions and devices characterized by in vitro maturation of oocytes. In particular, the present disclosure features methods of inducing oocyte maturation in vitro by co-culturing oocytes of a female subject with an ex vivo composition comprising a plurality of ovarian supporting cells (e.g., granular cells). Additional methods of administering a follicle triggering agent and extracting oocytes from a female subject are also provided. Such methods, compositions, and devices are particularly useful for assisted reproductive technology (ART) procedures.

The invention belongs to the technical field of immunodetection, and discloses a rabbit monoclonal antibody mAb6 of an anti-mouse immune globulin G2a subtype (IgG2a) and application thereof. The rabbit monoclonal antibody mAb6 comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1-3, the LCDR1 comprises an amino acid sequence KSVYKNNY, the LCDR2 comprises an amino acid sequence GTN, and the LCDR3 comprises an amino acid sequence AGGYID; the heavy chain variable region comprises HCDR1-3, the HCDR1 comprises an amino acid sequence RFSLSNYR, the HCDR2 comprises an amino acid sequence IFTRGST, and the HCDR3 comprises an amino acid sequence ARGWNS. The rabbit monoclonal antibody disclosed by the invention can be combined with a mouse immune globulin G2a subtype (IgG2a) in a high-specificity manner, can be applied to immunodetection, and provides a basis for further preparation of engineering antibodies.

The invention provides a system for evaluating an ADE effect in vitro and application of the system. The system comprises: (i) and (iii); (ii) and (iii); or (i), (ii) and (iii); in one embodiment, the present invention relates to a cell comprising: (i) an SARS-CoV-2 pseudovirus, (ii) an antibody that targets the receptor binding domain of SARS-CoV-2, and (iii) a cell that overexpresses CD32B; the cells are CHO cells. The system provided by the invention can be used for evaluating the ADE effect of the to-be-detected SARS-CoV-2 or the pseudovirus prepared from the to-be-detected SARS-CoV-2 or the antibody targeting the SARS-CoV-2, and has the advantage of higher sensitivity compared with a system based on cells expressing CD32A. The ADE evaluation system has a wide detection range, and can evaluate the ADE effect caused by the action of the SARS-CoV-2 virus or the pseudovirus prepared from the SARS-CoV-2 virus on CHO-CD32B in the presence of the RBD antibody with a wide concentration range (16 ng / mL-10000 ng / mL).

The invention relates to application of pirfenidone in preparation of testicular organs, and the pirfenidone can improve one or more properties and / or functions of the testicular organs, especially improve blood testis barriers and improve spermatogenesis efficiency. The invention also provides a method, a culture medium and a kit for preparing the testicular organoid.

The present invention is related to the field of protein engineering technology which increases the enzymatic activity and thermal stability of human hyaluronidase which is an enzyme that hydrolyzes hyaluronic acid; and more particularly to hyaluronidase PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions in the region corresponding to the alpha-helix region and its linker region in the amino acid sequence of wild-type PH20 of SEQ ID NO: 1 and in which one or more amino acid residues at the N-terminus and / or the C-terminus are selectively cleaved additionally.Specifically, the present invention relates to PH20 variants or fragments thereof, which comprise one or more amino acid residue substitutions selected from the group consisting of T341A, T341C, T341G, S343E, M345T, K349E, L353A, L354I, N356E and I361T in wild-type PH20 having the amino acid sequence of SEQ ID NO: 1, and additionally comprise the substitution of amino acids located in the alpha-helix 8 region and / or a linker region between alpha-helix 7 and alpha-helix 8 in the amino acid sequence of wild-type PH20, and in which one or more amino acids located at the N-terminal and C-terminal regions are deleted.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb32 or an antigen binding fragment, the anti-T3 antibody mAb32 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is IAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb32 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, and when a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.

Provided are a fusion protein (for example, in the form of a bispecific antibody) binding to CD235a and CD3, a preparation method therefor, and a related use thereof.

The invention belongs to the technical field of immunodetection, and discloses an anti-T3 antibody mAb68 or an antigen binding fragment, the anti-T3 antibody mAb68 or the antigen binding fragment comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises LCDR1, LCDR2 and LCDR3, the amino acid sequence of the LCDR1 is shown as SEQ ID NO.1, the amino acid sequence of the LCDR2 is TAS, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.3; the heavy variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 are respectively shown as SEQ ID NO. 4-6. When the anti-T3 antibody mAb68 is used for detecting a T3 standard antigen, the detection sensitivity is lower than 0.2 ng / ml, a clinical sample is detected through a magnetochemiluminescence method, and the correlation with R clinical comparison is good within the sample range of 1-80 pmol / L.

The invention discloses a CD40L-IL-2 fusion protein, preparation thereof and application of the CD40L-IL-2 fusion protein in preparation of drugs for treating tumors. The fusion protein comprises a CD40L trimer or a variant thereof, and a cytokine IL-2 or a variant thereof; the CD40L trimer comprises three CD40L monomers which are connected with one another. The fusion protein provided by the invention can synergistically activate APC-dependent antigen presentation and T cell-mediated immune killing to form closed-loop anti-tumor immune response of antigen presentation-immune initiation-effect amplification, and an effective strategy is provided for tumor treatment.

The invention relates to a targeted CLDN18.2 antigen binding protein and application thereof, the antigen binding protein comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises an amino acid sequence as shown in SEQ ID NO: 10, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 3.

The invention discloses a system for evaluating an ADE effect and application thereof. The system comprises: (i) and (iii); (ii) and (iii); or (i), (ii) and (iii); (i) is a Middle East Respiratory Syndrome Coronavirus pseudovirus, (ii) is an antibody that targets the receptor binding domain of the Middle East Respiratory Syndrome Coronavirus, and (iii) is a cell that overexpresses CD32B; the cells are CHO cells; the pseudovirus contains a Spike protein coding gene of the Middle East Respiratory Syndrome Coronavirus. According to the invention, the ADE activity of the Middle East respiratory coronavirus antibody is identified in vitro by using MERS-CoV pseudovirus and cells for exogenous expression of CD32B. Compared with an immune cell Raji and an ADE evaluation system based on exogenous expression CD32A cells, the system provided by the invention is more sensitive, and is a potential system for evaluating the ADE effect of the Middle East respiratory coronavirus.

The present invention relates to a nanobody or antigen-binding fragment thereof that specifically binds to serum albumin, a derivative comprising the nanobody or the antigen-binding fragment thereof, a nucleic acid encoding the antibody or antigen-binding fragment thereof, a host cell comprising same, and related uses. Further, the present invention relates to therapeutic use of the antibody or the antigen-binding fragment thereof or the derivative.

The invention belongs to the technical field of genes, and discloses a method for efficiently expressing a foreign protein based on an NC048604-1 site in a CHO cell genome. A site for stably expressing protein in the CHO cell genome is located in the 94142000 to 94148000 basic group range of the CHO cell genome NC048604-1, and the nucleotide sequence of the site is as shown in SEQ ID NO: 1. According to the invention, different protein genes are introduced at fixed positions in a CHO cell genome, and stable expression is carried out.

The present invention provides: a drug which can improve the implantation rate of an embryo and can be used in conjunction with conventional drugs for infertility treatment; and a screening method and the like with which it is possible to reliably evaluate such a drug. Specifically, the integrin activator comprises: (1) a peptide composed of KFEERMRCKWMT, and (2) a peptide composed of KFEERMRCKWMT. (2) a peptide which is composed of KFEEERSRCKWMT; (3) a peptide comprising an amino acid sequence obtained by deleting, substituting and / or adding 1-3 amino acids in (1) or (2); or (4) a peptide obtained by binding any one of (1) to (3) to a membrane-permeable molecule. Provided are an artificial uterus and a screening method based on an implantation reproduction test system using a fertilized egg (for example, an embryo developed to an implanted blastocyst), the artificial uterus comprising: a hydrogel containing endometrial stromal cells and having an extracellular matrix as a main component; and a uterine epithelial organoid configured to be surrounded by the hydrogel.

The invention relates to the technical field of virology, immunology and biomedicine, in particular to a human metapneumovirus F protein mutant and application thereof. The human metapneumovirus F protein mutant provided by the invention has stable prefusion conformation and high expression quantity, and can form a stable trimer, so that the human metapneumovirus F protein mutant can be used for HMPV vaccine development. The F protein mutant provided by the invention has excellent immunogenicity, and can induce excellent immune response when being used together with an HA201 composite adjuvant (QS21 + MPL liposome).

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granular cell-like cells by overexpressing transcription factors (e.g., NR5A1 and RUNX family proteins (e.g., RUNX1 and / or RUNX2).

A pharmaceutical composition according to an aspect can be applied to the prevention, treatment or the like of endometrial damage, Asherman's syndrome, or complications thereof by: reducing the level of collagen accumulation in the endometrium; increasing the expression level of VEGF; increasing the expression level of Ki67; increasing the expression level of Itgb3; increasing the expression level of Spp1; increasing the number of implantation sites; decreasing the expression levels of fibrosis-related factors; decreasing the expression levels of metabolism-related factors; increasing ATP production; and regulating the expression levels of mitochondrial function-related factors.

The present invention proposes a growth hormone fusion protein and its application. The fusion protein includes an Fc mutant, which includes: a first peptide chain, wherein the first peptide chain 1) has a mutation at the following sites compared to the wild-type IgG4Fc fragment: at least one of the 234th, 235th, 298th, 299th, and 300th positions; or 231-239th positions; or 2) has a mutation at the following sites compared to the wild-type IgG1Fc fragment: at least one of the 228th-239th positions, and / or at least one of the 268th, 296th, 330th, and 331st positions. The fusion protein has a strong binding activity with human growth hormone receptors, can eliminate ADCC and CDC effects, promote Nb2-11 cell proliferation, and thus effectively treat or prevent diseases related to abnormal human growth hormone.

The present disclosure relates to novel antibodies binding to GPC3 or antigen-binding fragments thereof. These anti-GPC3 antibodies or fragments thereof preferably don't comprise lysine residues within their CDRs and are therefore especially suitable for conjugation. The present disclosure further relates to targeted radionuclide conjugates such as targeted actinium-225 conjugates (TACs). Preferred are TACs of formula (I) comprising the anti-GPC3 antibodies according to the present disclosure or fragments thereof. Said antibodies or antigen binding fragments thereof, and / or said antibody conjugates and / or said TACs are useful in diagnostics and / or therapy, preferably in therapy, more preferably in treating cancer, most preferably in treating hepatocellular carcinoma (HCC). Provided are pharmaceutical compositions and kits with instructions for use comprising these antibodies, functional fragments and conjugates. The disclosure further provides methods and tools to generate these antibodies, functional fragments and conjugates.

The present disclosure provides anti-TNFR2 (tumor necrosis factor receptor 2) antibodies, antigen-binding fragments thereof, and uses thereof.